These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 27009256

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D.
    de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV.
    Neurology; 2021 Apr 20; 96(16):e2132-e2137. PubMed ID: 33692164
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
    Sharma M, Vadhariya A, Johnson ML, Marcum ZA, Holmes HM.
    BMC Health Serv Res; 2018 Apr 02; 18(1):236. PubMed ID: 29609611
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Medicare Part D payments for brand and generic drugs prescribed by dermatologists.
    Powell HB, Adamson AS.
    J Am Acad Dermatol; 2018 Sep 02; 79(3):575-577. PubMed ID: 29477736
    [No Abstract] [Full Text] [Related]

  • 9. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
    Duarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, Ross JS, Matteson EL, Shah ND.
    Mayo Clin Proc; 2022 Feb 02; 97(2):250-260. PubMed ID: 35120693
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Medicare part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect".
    Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS, Mylonakis E.
    PLoS One; 2018 Feb 02; 13(6):e0198674. PubMed ID: 29879194
    [Abstract] [Full Text] [Related]

  • 15. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H, Adamson A, Mostaghimi A.
    JAMA Dermatol; 2017 Aug 01; 153(8):755-759. PubMed ID: 28453645
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
    Sumarsono A, Sumarsono N, Das SR, Vaduganathan M, Agrawal D, Pandey A.
    JAMA Netw Open; 2020 Feb 05; 3(2):e200181. PubMed ID: 32108893
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.